PDF(Pubmed)
Abstract：
Despite successful vaccines and updates, constant mutations of SARS-CoV-2 makes necessary the search for new vaccines. We generated a chimeric protein that comprises the receptor-binding domain from spike and the nucleocapsid antigens (SpiN) from SARS-CoV-2. Once SpiN elicits a protective immune response in rodents, here we show that convalescent and previously vaccinated individuals respond to SpiN. CD4+ and CD8+ T cells from these individuals produced greater amounts of IFN-γ when stimulated with SpiN, compared to SARS-CoV-2 antigens. Also, B cells from these individuals were able to secrete antibodies that recognize SpiN. When administered as a boost dose in mice previously immunized with CoronaVac, ChAdOx1-S or BNT162b2, SpiN was able to induce a greater or equivalent immune response to homologous prime/boost. Our data reveal the ability of SpiN to induce cellular and humoral responses in vaccinated human donors, rendering it a promising candidate.
摘要：
尽管成功的疫苗和更新，SARS-CoV-2的恒定突变使得有必要寻找新的疫苗。我们产生了一种嵌合蛋白，该蛋白包含来自刺突的受体结合域和来自SARS-CoV-2的核衣壳抗原（SpiN）。一旦SpiN在啮齿动物中引发保护性免疫反应，在这里，我们表明，恢复期和以前接种过疫苗的个体对SpiN有反应。当用SpiN刺激时，来自这些个体的CD4+和CD8+T细胞产生更大量的IFN-γ，与SARS-CoV-2抗原相比。此外，来自这些个体的B细胞能够分泌识别SpiN的抗体。当在先前用CoronaVac免疫的小鼠中作为加强剂量给药时，ChAdOx1-S或BNT162b2,SpiN能够诱导对同源引发/加强的更大或等同的免疫应答。我们的数据揭示了SpiN在接种疫苗的人类供体中诱导细胞和体液反应的能力，使它成为一个有前途的候选人。
